Skip to main content

Gilead Sciences, Inc. (GILD) Stock

Gilead Sciences, Inc. Stock Details, Movements and Public Alerts

Stock Details

Gilead Sciences, Inc. (GILD), a prominent company in the healthcare sector within the drug manufacturers - general industry, is based in United States and primarily trades on the NMS.Currently, the stock is trading at $170.50. Over the past 52 weeks, it has ranged between $114.02 and $175.65. This places the current price at 97.1% of its 52-week high and 49.5% above its 52-week low. Recent trading volume was recorded at 11,426,134. The 14-day Relative Strength Index (RSI) stands at 74.36, suggesting overbought conditions. The stock is currently trading above its 50-day moving average of $150.33 by 13.42%. Similarly, it is above its 200-day moving average of $139.88 by 21.89%. The MACD histogram is 1.35, indicating bullish momentum (MACD Line: 4.35, Signal Line: 3.00). The International Securities Identification Number (ISIN) for this stock is US3755581036. There is currently 1 active alert set for GILD by users.

52-Week Range

$175.65 - $114.02

-2.93% from high · +49.54% from low

Avg Daily Volume

6,262,424

20-day average

100-day avg: 6,655,030

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Forward P/E

17.10

PEG Ratio

2.45

Potentially overvalued

Price to Book

9.33

EV/EBITDA

15.52

EPS (TTM)

-$2.65

Price to Sales

6.95

Beta

0.33

Less volatile than market

Q:How is GILD valued relative to its earnings and growth?
Valuation data is not available for this stock.
Q:What is GILD's risk profile compared to the market?
With a beta of 0.33, Gilead Sciences, Inc. is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 9.33 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

-10.64%

Operating Margin

33.68%

EBITDA

$14.60B

Return on Equity

-20.68%

Return on Assets

14.09%

Revenue Growth (YoY)

10.20%

Q:How profitable and efficient is GILD's business model?
Gilead Sciences, Inc. achieves a profit margin of -10.64%, meaning it retains $-10.64 from every $100 in revenue after all expenses. This relatively low margin suggests the company operates in a competitive environment or high-cost industry where profitability is challenging. The operating margin of 33.68% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at -20.68% and ROA at 14.09%, the company achieves moderate returns on invested capital.
Q:What are GILD's recent growth trends?
Gilead Sciences, Inc.'s revenue grew by 10.20% year-over-year, showing steady progress in growing the business. This positive trajectory indicates the company maintains competitive positioning in its markets. These growth metrics should be evaluated against Drug Manufacturers - General industry averages for proper context.

Dividend Information

Dividend Per Share

$3.28

Dividend Yield

1.98%

Ex-Dividend Date

Sep 15, 2026

Dividend Date

Sep 29, 2026

Q:What dividend income can investors expect from GILD?
Gilead Sciences, Inc. offers a dividend yield of 1.98%, paying $3.28 per share annually. This modest yield below 2% suggests the company prioritizes growth investments over current income. While the dividend provides some return, investors are likely attracted more by capital appreciation potential than income generation. To receive the next dividend, shares must be purchased before the ex-dividend date of Sep 15, 2026.
Q:How reliable is GILD's dividend for long-term investors?
The dividend sustainability can be assessed through the payout ratio - Gilead Sciences, Inc. pays $3.28 per share in dividends against earnings of -$2.65 per share, resulting in a payout ratio of -123.77%. This conservative payout below 30% indicates excellent dividend safety with substantial room for future increases. The company retains most earnings for growth while still rewarding shareholders. The next dividend payment is scheduled for Sep 29, 2026.

Company Size & Market

Market Cap

$211.8B

Revenue (TTM)

$30.46B

Revenue/Share (TTM)

$24.51

Shares Outstanding

1.24B

Book Value/Share

$18.29

Asset Type

EQUITY

Q:What is GILD's market capitalization and position?
Gilead Sciences, Inc. has a market capitalization of $211.8B, classifying it as a mega-cap stock (over $200B). These are the largest, most established companies globally, typically offering stability and liquidity but with more modest growth potential. Mega-caps often pay dividends and weather economic downturns better than smaller companies. With 1.24B shares outstanding, the company's ownership is widely distributed. As a major player in the Drug Manufacturers - General industry, it competes with other firms in this sector.
Q:How does GILD's price compare to its book value?
Gilead Sciences, Inc.'s book value per share is $18.29, while the current stock price is $170.50, resulting in a price-to-book (P/B) ratio of 9.32. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As EQUITY, this represents a specific type of security.

Analyst Ratings

Analyst Target Price

$160.19

6.05% downside potential

Analyst Recommendations

Strong Buy

5

Buy

18

Hold

8

Sell

0

Strong Sell

0

Q:How reliable are analyst predictions for GILD?
31 analysts cover GILD with 74% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $160.19 implies -6.0% downside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on GILD?
Current analyst recommendations:5 Strong Buy, 18 Buy, 8 Hold, 00The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Oct 31, 2026, 02:07 AM

Technical Indicators

RSI (14-day)

74.36

Overbought

50-Day Moving Average

$150.33

13.42% above MA-50

200-Day Moving Average

$139.88

21.89% above MA-200

MACD Line

4.35

MACD Signal

3.00

MACD Histogram

1.35

Bullish

Q:What does GILD's RSI value tell investors?
The RSI (Relative Strength Index) for GILD is currently 74.36, indicating the stock is in overbought territory (above 70). This suggests strong recent buying pressure that may be unsustainable. While overbought conditions can persist in strong trends, traders often watch for RSI divergences or a drop below 70 as potential sell signals. Combined with the price being above the 50-day moving average, this confirms bullish conditions.
Q:How should traders interpret GILD's MACD and moving average crossovers?
MACD analysis shows the MACD line at 4.35 above the signal line at 3.00, with histogram at 1.35. This bullish crossover suggests upward momentum is building. The wide histogram confirms strong momentum. The 50-day MA ($150.33) is above the 200-day MA ($139.88), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently above both MAs, confirming strength.

Indicators last updated: Oct 31, 2026, 12:43 AM

Active Alerts

Alert Condition
Price decreases by
Threshold
20%
Created
Apr 27, 2026, 09:02 PM

Stay Ahead of the Market with Gilead Sciences, Inc. Alerts

Set up price alerts for Gilead Sciences, Inc. and get notified instantly when the price hits your target. Never miss an important price movement again.